Genentech loses bid to put Lucentis on fast track

The FDA has rejected Genentech's bid to put its experimental drug for wet, age-related macular degeneration on a regulatory fast track. Genentech, however, said the rejection won't affect its planned submission of the drug for regulatory approval in December. Genentech also plans to launch another late-stage trial of Lucentis by year's end. Drug developers have been closely following Lucentis, which many believe has the potential to outperform Eyetech's recently-approved Macugen.

- read this AP story for more

ALSO: The TNKase clot-busting drug from Genentech and Ingelheim Boehringer is not safe for opening arteries prior to angioplasty, according to the results of a new study. Story